Curanex Pharmaceuticals Inc
CURX
$4.20
-$0.84-16.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1,168.28% | 574.33% | 981.57% | 193.57% | 30.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5,663.60% | 2,215.20% | 4,153.92% | 919.61% | 30.54% |
| Operating Income | -5,663.60% | -2,215.20% | -4,153.92% | -919.61% | -30.54% |
| Income Before Tax | -5,357.71% | -2,189.39% | -2,006.31% | -946.16% | -36.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5,357.71% | -2,189.39% | -2,006.31% | -946.16% | -36.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5,357.71% | -2,189.39% | -2,006.31% | -946.16% | -36.43% |
| EBIT | -5,663.60% | -2,215.20% | -4,153.92% | -919.61% | -30.54% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4,513.32% | -1,837.93% | -2,900.42% | 1.88% | 86.34% |
| Normalized Basic EPS | -4,518.79% | -1,837.66% | -6,054.09% | 1.87% | 86.36% |
| EPS Diluted | -4,513.32% | -1,837.93% | -2,900.42% | 1.88% | 86.34% |
| Normalized Diluted EPS | -4,518.79% | -1,837.66% | -6,054.09% | 1.87% | 86.36% |
| Average Basic Shares Outstanding | 18.18% | 18.10% | -29.83% | 966.67% | 900.00% |
| Average Diluted Shares Outstanding | 18.18% | 18.10% | -29.83% | 966.67% | 900.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |